Peptide Biologix
Compound index
The atlas

MOTS-c: Comprehensive Research Monograph and Technical Review

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid mitochondrial-derived peptide (MRWQEMGYIFYPRKLR; CAS 1627580-64-6) encoded by a short open reading frame within the mitochondrial 12S rRNA gene (MT-RNR1, nucleotides 1382–1432). Discovered by Lee and colleagues in 2015, MOTS-c regulates systemic metabolic homeostasis via the folate–AICAR–AMPK pathway and translocates to the cell nucleus during metabolic stress to coordinate adaptive antioxidant and stress-response gene expression.

Translucent leaf study showing a delicate internal vein structure
Plate 21MOTS-c
Primary Structure (16-Residue Mitochondrial-Encoded Peptide) H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH (MRWQEMGYIFYPRKLR)
Regulatory & Compounding Status (April 2026): On FDA’s page on bulk drug substances used in compounding, current as of April 22, 2026, MOTS-c is listed as nominated for Category 2, but withdrawn. MOTS-c is not an FDA-approved human or veterinary drug and is listed on the World Anti-Doping Agency (WADA) Prohibited List under section S4.4 (Metabolic Modulators / AMPK activators). All content in this monograph is strictly for laboratory research and academic reference.

1. Overview and Key Characteristics

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is a 16-amino-acid bioactive peptide encoded within the mitochondrial genome that acts as an endocrine and autocrine/paracrine regulator of cellular metabolism, insulin sensitivity, and stress adaptation [Lee et al., Cell Metab 2015; PMID: 25738459]. MOTS-c is encoded within the mitochondrial 12S rRNA locus (MT-RNR1).

Skeletal muscle serves as the primary target organ of MOTS-c action, where the peptide inhibits the folate-methionine cycle, elevates endogenous 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), activates AMP-activated protein kinase (AMPK), and stimulates GLUT4-mediated glucose uptake and fatty acid β-oxidation. In addition, MOTS-c was the first mitochondrial-encoded peptide shown to translocate directly to the cell nucleus in response to glucose restriction or oxidative stress, where it interacts with stress-responsive transcription factors including NRF2 (NFE2L2) and ATF1 to regulate nuclear gene expression [Kim et al., Cell Metab 2018; PMID: 29983246].

Key Research Highlights

  • Mitochondrial Genome Origin: Encoded within mtDNA 12S rRNA (nt 1382–1432)
  • Folate–AICAR–AMPK Axis: Inhibits folate cycle enzyme MTHFD, accumulating endogenous AICAR (up to 20-fold) and activating AMPK without depleting cellular ATP
  • Retrograde Nuclear Signaling: Translocates to the nucleus in response to metabolic stress in an AMPK-dependent manner to bind ARE promoter regions alongside NRF2
  • Exercise-Induced Mitokine: Acute aerobic and resistance exercise elevates skeletal muscle MOTS-c expression ~11.9-fold and circulating plasma MOTS-c ~1.5–1.6-fold in humans [Reynolds et al., Nat Commun 2021]
  • Longevity Polymorphism (K14Q): An East Asian-specific mtDNA variant (m.1382A>C, substituting Lys14 with Gln14) is enriched in Japanese centenarians [Fuku et al., Aging Cell 2015]

2. Chemical Structure and Molecular Properties

MOTS-c is a linear hexadecapeptide with the primary amino acid sequence H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH (single-letter code: MRWQEMGYIFYPRKLR). The sequence contains two methionine residues (Met1 and Met6), with molecular formula C101H152N28O22S2 and monoisotopic mass 2174.62 Da.

Table 1: Molecular Specifications of MOTS-c
Property Specification
Peptide Name MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c)
Genomic Locus Mitochondrial DNA 12S rRNA gene (MT-RNR1, nucleotides 1382–1432)
Sequence (Single-Letter) MRWQEMGYIFYPRKLR (16 amino acids)
Sequence (Three-Letter) Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg
Molecular Formula C101H152N28O22S2
Molecular Weight 2174.62 Da
CAS Registry Number 1627580-64-6
Isoelectric Point (pI) ~10.7
Net Charge at pH 7.4 +4.0 (three Arg, one Lys, one Glu)
GRAVY Index -0.456 (moderately hydrophilic / amphipathic)
Molar Extinction Coefficient (ε280) 11,460 M-1cm-1 (one Trp, two Tyr)
Human Polymorphism Variant K14Q variant (m.1382A>C): MRWQEMGYIFYPRQLR

2.1 Domain Architecture and Structure-Activity Relationships

Structure-activity relationship studies indicate that MOTS-c comprises two functionally specialized regions:

  • N-Terminal / Central Hydrophobic-Aromatic Core (Residues 1–11, MRWQEMGYIFY): Contains two methionines (Met1, Met6) and four bulky aromatic residues (Trp3, Tyr8, Phe10, Tyr11). The Tyr8-Ile9-Phe10-Tyr11 motif is indispensable for both cytoplasmic AMPK activation and hydrophobic interaction with nuclear import machinery; truncation or alanine substitution within residues 8–11 abolishes biological activity.
  • C-Terminal Polybasic Region (Residues 12–16, PRKLR): Initiated by a turn-inducing Pro12 residue followed by a dense cluster of positively charged residues (Arg13-Lys14-Leu15-Arg16). This cationic tail resembles cell-penetrating peptide (CPP) and nuclear localization signal (NLS) motifs, facilitating plasma membrane translocation and nuclear pore import. The naturally occurring K14Q polymorphism (replacing positively charged Lys14 with neutral Gln14) reduces net charge from +4 to +3 and alters insulin-sensitizing potency in a sex- and activity-dependent manner [Fuku et al., Aging Cell 2015].

3. Mechanism of Action and Signaling Pathways

MOTS-c operates as a dual-compartment signaling molecule, regulating intermediary metabolism in the cytoplasm and transcriptional adaptation in the nucleus.

Table 2: Primary Molecular Targets and Downstream Signaling Effects of MOTS-c
Molecular Pathway Direct / Proximal Effect Downstream Physiological Outcome
Folate–Methionine Cycle (MTHFD / 5-methyl-THF) Inhibition of folate cycle enzymes; depletion of 5-methyl-THF; blockade of de novo purine synthesis Up to 20-fold intracellular accumulation of endogenous AICAR
AMPK (Thr172) & ACC (Ser79) Allosteric and LKB1-mediated activation of AMPK; inhibitory phosphorylation of acetyl-CoA carboxylase Enhanced GLUT4 translocation, insulin-sensitized glucose uptake, and mitochondrial fatty acid β-oxidation
Retrograde Nuclear Translocation (NRF2 / ARE) AMPK-dependent nuclear import during metabolic stress; direct binding to ARE promoter regions with NRF2/ATF1 Transcriptional upregulation of antioxidant (HO-1, NQO1) and proteostatic stress-response genes
PGC-1α & Mitochondrial Biogenesis Increased PGC-1α, TFAM, and NRF1 expression; mitofusin (MFN2) upregulation Increased mitochondrial copy number, cristae density, and respiratory capacity
Myostatin / FOXO1 / AKT Pathway Inhibition of myostatin expression and FOXO1 nuclear localization via AKT(Ser473) phosphorylation Prevention of high-fat-diet and immobilization-induced skeletal muscle atrophy
NF-κB & Inflammatory Cytokines Suppression of NF-κB activation and NLRP3 inflammasome signaling Decreased IL-1β, IL-6, and TNF-α in metabolic, vascular, and osteolytic tissues

3.1 The Folate–AICAR–AMPK Metabolic Axis

In their 2015 discovery paper, Lee et al. performed unbiased metabolomic profiling in HEK293 and C2C12 myoblast cells stably expressing or treated with MOTS-c [Lee et al., Cell Metab 2015]. MOTS-c selectively reduced intracellular 5-methyltetrahydrofolate (5Me-THF) and methionine levels by inhibiting folate cycle enzymes (including methylenetetrahydrofolate dehydrogenase, MTHFD). Folate-cycle modulation leads to AICAR accumulation. Endogenous AICAR acts as an AMP mimetic (ZMP), allosterically activating AMPK (phosphorylating α-subunit Thr172), which in turn phosphorylates acetyl-CoA carboxylase (ACC at Ser79), lowers malonyl-CoA, relieves carnitine palmitoyltransferase-1 (CPT-1) inhibition to accelerate fatty acid β-oxidation, and promotes TBC1D1/AS160-mediated GLUT4 vesicle translocation to the sarcolemma.

3.2 Retrograde Mitochondrial-to-Nuclear Translocation

Under basal conditions, endogenous MOTS-c resides primarily in the cytoplasm and colocalizes with mitochondria. However, Kim et al. (2018) demonstrated that in response to metabolic stress (such as glucose deprivation, serum starvation, or tert-butyl hydroperoxide exposure), MOTS-c rapidly translocates into the nucleus via an AMPK-dependent mechanism requiring its hydrophobic core [Kim et al., Cell Metab 2018]. Chromatin immunoprecipitation sequencing (ChIP-seq) and biochemical pull-down studies revealed that nuclear MOTS-c binds directly to 5′-UTR and promoter regions containing Antioxidant Response Elements (ARE), forming complexes with stress-activated transcription factors NRF2 (NFE2L2) and ATF1 to reprogram nuclear gene expression toward cellular stress resistance.

4. Preclinical Research and Animal Studies

Preclinical studies across rodent models of diet-induced obesity, insulin resistance, aging, physical performance, diabetic cardiomyopathy, and ovariectomy-induced bone/metabolic dysfunction have documented broad systemic actions of MOTS-c.

Table 3: Summary of Major Preclinical Findings with MOTS-c
Research Domain Animal Model Regimen Reported Outcomes
Diet-Induced Obesity & Insulin Resistance High-fat diet (HFD) C57BL/6 mice 0.5–5 mg/kg/day IP for 8 weeks Prevented HFD-induced weight gain and hepatic steatosis; increased skeletal muscle glucose clearance by ~30% in hyperinsulinemic-euglycemic clamps without altering food intake [Lee et al., 2015]
Age-Related Insulin Resistance Middle-aged (12 mo) & old (22 mo) mice 5–15 mg/kg IP daily for 7–14 days Restored skeletal muscle insulin-stimulated glucose uptake in aged mice to youthful levels [Lee et al., 2015]
Physical Capacity & Late-Life Healthspan Young (2 mo), middle-aged (12 mo), and old (22–24 mo) C57BL/6N mice 5–15 mg/kg IP daily or 3x/week Doubled treadmill running distance/time across age groups; late-life initiation at 23.5 months improved grip strength, stride length, and trended toward increased median survival [Reynolds et al., 2021]
Ovariectomy-Induced Metabolic Dysfunction Ovariectomized (OVX) female mice 5 mg/kg/day IP Attenuated adipose hypertrophy, improved brown adipose thermogenesis, and restored insulin sensitivity [Lu et al., 2022]
Ovarian Cancer Xenografts Murine ovarian carcinoma models Systemic peptide administration Promoted USP7-dissociation and ubiquitination-mediated degradation of leucyl-tRNA synthetase 1 (LARS1), suppressing tumor progression [Ming et al., 2024]

5. Human Studies and Clinical Research

Human research on MOTS-c encompasses observational biomarker studies in metabolic and exercise cohorts, population-genetics analyses of the m.1382A>C (K14Q) polymorphism, and Phase 1a/1b clinical trials of the synthetic MOTS-c analog CB4211.

Table 4: Summary of Human Clinical, Exercise, and Epidemiological Studies
Study Category Population / Compound Design / Sample Size Key Findings
CB4211 Phase 1a/1b Trial Healthy volunteers & subjects with NAFLD/obesity (MOTS-c analog CB4211) Randomized, double-blind, placebo-controlled (Phase 1a/1b) Favorable tolerability with no serious adverse events; Phase 1b showed statistically significant reductions in ALT, AST, fasting glucose, and body weight
Human Acute Exercise Study [Reynolds et al., 2021] Healthy young sedentary men (n=10) High-intensity interval cycling with serial vastus lateralis biopsies & plasma sampling Skeletal muscle MOTS-c rose 11.9-fold post-exercise; circulating plasma MOTS-c increased 1.6-fold during exercise and 1.5-fold during recovery
Centenarian & Longevity Genetics [Fuku et al., 2015] Japanese centenarian and control cohorts Mitochondrial haplogroup & m.1382A>C (K14Q) genotyping Enrichment of the m.1382A>C variant within haplogroup D4b2, associated with exceptional longevity and muscle fiber composition in East Asian populations
Insulin Sensitivity Association [Cataldo et al., 2018] Lean and obese human adults Cross-sectional clamp / HOMA-IR analysis Plasma MOTS-c concentrations positively correlated with insulin sensitivity in lean individuals; blunted in obesity and type 2 diabetes

6. Analytical Methods and Quality Assessment

Analytical verification of synthetic MOTS-c requires orthogonal chromatographic and mass spectrometric methods capable of resolving the intact 16-mer from deletion sequences and oxidized methionine species.

6.1 RP-HPLC, Mass Spectrometry, and Methionine Oxidation Control

Because MOTS-c contains two methionine residues (Met1 and Met6) as well as Trp3, Tyr8, and Tyr11, dual-wavelength UV detection at 220 nm (peptide backbone) and 280 nm (ε280 = 11,460 M-1cm-1) on a C18 column is standard. Mono-oxidized methionine sulfoxide species ([M+O], 2190.62 Da, +16 Da) and di-oxidized species ([M+2O], 2206.62 Da, +32 Da) elute ahead of the native 2174.62 Da peak due to increased polarity and must be quantified at <2.0% total oxidized impurities to preserve biological potency.

Table 5: Analytical Characterization Methods for MOTS-c
Technique Purpose Key Specifications
RP-HPLC (UV detection) Purity assessment ≥98% main peak at 220 nm; baseline resolution of impurities
ESI-MS or MALDI-TOF MS Molecular weight confirmation 2174.62 ± 1.0 Da (monoisotopic mass)
MS/MS sequencing Sequence verification 100% match to MRWQEMGYIFYPRKLR; all b- and y-ions detected
Amino acid analysis Compositional analysis All residues within ±10% of theoretical molar ratios
Peptide mapping (LC-MS) Sequence and modification analysis Tryptic digest analysis; detection of oxidation or modifications
Karl Fischer titration Water content ≤8.0% (lyophilized powder)
Ion chromatography Counter-ion quantification TFA ≤0.1%; acetate as specified by formulation
UV-Vis spectroscopy Concentration determination Using ε280 = 11,460 M-1cm-1
LAL endotoxin assay Bacterial endotoxin testing ≤5 EU/mg (for injectable formulations)

6.2 Biological Activity Assays

Cell-based assays measuring AMPK(Thr172) and downstream ACC(Ser79) phosphorylation in C2C12 myoblasts or primary skeletal muscle cells, 2-deoxy-D-glucose uptake assays (demonstrating 25–50% increases over vehicle control), and stress-induced nuclear translocation immunofluorescence assays provide functional verification that synthetic MOTS-c retains full biological activity.

6.3 Quantification in Biological Samples

Measurement of endogenous MOTS-c in plasma, serum, or tissue samples requires sensitive and specific analytical methods. Enzyme-linked immunosorbent assays (ELISA) using anti-MOTS-c antibodies provide high-throughput quantification but may suffer from cross-reactivity or matrix effects. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) offers superior specificity and accuracy, representing the gold standard for MOTS-c bioanalysis.

LC-MS/MS methods for MOTS-c typically employ immunoaffinity enrichment or solid-phase extraction to concentrate the peptide from complex biological matrices, followed by reversed-phase liquid chromatography separation and MS/MS detection using multiple reaction monitoring (MRM). Stable isotope-labeled MOTS-c internal standard (heavy lysine or arginine incorporation) enables accurate quantification by correcting for matrix effects and recovery variations. Typical lower limits of quantification (LLOQ) are 0.5–5 ng/mL in plasma, sufficient for measuring physiological concentrations.

7. Research Applications and Experimental Uses

MOTS-c is widely utilized as an experimental probe in metabolic disease modeling (dissecting folate-AICAR-AMPK signaling vs. biguanide Complex I inhibition), aging and longevity biology (studying age-dependent decline in mitochondrial retrograde signaling alongside Humanin and Epithalon), and exercise physiology (comparing mitokine-driven PGC-1α biogenesis with growth-hormone secretagogues such as Ipamorelin and Sermorelin).

8. Preclinical Dosing Paradigms in Research Settings

Published rodent studies have used systemic MOTS-c doses ranging from 0.5 mg/kg to 15 mg/kg body weight via intraperitoneal (IP) or subcutaneous (SC) injection, with most metabolic and performance studies employing doses of 0.5–5 mg/kg:

Table 6: Representative Preclinical Dosing Protocols Reported in Literature Literature summary of published study doses, routes, and schedules.
Application Animal Dose Range Route Frequency & Duration
Insulin resistance prevention 0.5–5 mg/kg IP, SC (rodent) Once daily for 4–8 weeks
Obesity prevention (HFD) 0.5–5 mg/kg IP, SC (rodent) Once daily during HFD (8–16 weeks)
Physical performance enhancement 0.5–5 mg/kg SC, IP (rodent) Once daily for 1–4 weeks
Age-related decline reversal 5–15 mg/kg SC, IP (rodent) 3x/week for 2–8 weeks
Acute metabolic signaling studies 5–10 mg/kg IP, IV (rodent) Single dose; assess 0.5–24h post-injection
Diabetes models (T1D, T2D) 1–10 mg/kg IP, SC (rodent) Once daily or 3x/week for 2–8 weeks
Cardiac protection (diabetic models) 5 mg/kg IP (rodent) Once daily for 4–8 weeks
Muscle atrophy prevention 5 mg/kg SC (rodent) Once daily during immobilization

9. Storage and Handling Protocols

Because Met1 and Met6 are susceptible to sulfoxidation and Trp3/Tyr8,11 are photosensitive, lyophilized MOTS-c should be stored desiccated and protected from light at -20°C to -80°C under inert gas.

Table 7: MOTS-c Laboratory Storage and Handling Guidelines
Form Storage Condition Stability Duration Special Considerations
Lyophilized powder (unopened) -80°C (ultra-low freezer) 24–36 months Optimal long-term storage; protect from moisture
Lyophilized powder (unopened) -20°C (freezer) 12–24 months Acceptable long-term storage; desiccated conditions
Lyophilized powder (unopened) 2–8°C (refrigerator) 3–6 months Short-term storage only; protect from moisture
Reconstituted (sterile water) 2–8°C (refrigerator) 7–14 days Use within recommended timeframe; protect from light
Reconstituted solution aliquots -20°C to -80°C (freezer) 1–3 months Single freeze-thaw only; thaw at 2–8°C before use

10. Safety Profile and Toxicology

Preclinical toxicology studies in rodents show no mortality or target-organ histopathology at doses up to 15 mg/kg (30-fold above the 0.5 mg/kg metabolic dose) over 8–16 weeks of chronic administration, and no hypoglycemia in normoglycemic animals. Standard bacterial reverse-mutation (Ames) assays are negative, and Phase 1a/1b clinical trials of the analog CB4211 reported transient mild injection-site reactions as the principal adverse event without systemic or cardiovascular toxicity. For comparative studies of longevity and immune-modulating peptides, see Epithalon, Thymosin Alpha-1, and GHK-Cu.

11. Literature Review and Research Trends

Since Lee et al. (2015) first identified MOTS-c as an mtDNA 12S rRNA-encoded metabolic hormone [Lee et al., Cell Metab 2015; PMID: 25738459] and Fuku et al. (2015) linked the m.1382A>C (K14Q) variant to Japanese centenarian longevity [Fuku et al., Aging Cell 2015; PMID: 26289118], subsequent studies by Kim et al. (2018) revealed stress-induced nuclear translocation [Kim et al., Cell Metab 2018; PMID: 29983246] and Reynolds et al. (2021) established MOTS-c as an exercise-induced mitokine reversing late-life physical decline [Reynolds et al., Nat Commun 2021; PMID: 33206854]. Recent reviews and experimental studies have expanded MOTS-c research into stress adaptation, adipose thermogenesis, and oncology models [Li et al., 2023]; [D'Souza et al., 2023]; [Ming et al., 2024].

12. References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459
  2. Kim KH, Son JM, Benayoun BA, Lee C. The mitochondrial-encoded peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress. Cell Metab. 2018;28(3):516-524.e7. PMID: 29983246
  3. Fuku N, Pareja-Galeano H, Zempo H, et al. The mitochondrial-derived peptide MOTS-c: a player in exceptional longevity? Aging Cell. 2015;14(6):921-923. PMID: 26289118
  4. Reynolds JC, Lai RW, Woodward JPN, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PMID: 33206854
  5. Li H, Wang C, He T, et al. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging. J Transl Med. 2023;21(1):36. PMID: 36698141
  6. D'Souza RF, Woodhead JST, Zeng N, et al. MOTS-c: a mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023;14:1096901. PMID: 36761202
  7. Cataldo LR, Fernández-Verdejo R, Santos JL, Galgani JE. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med. 2018;66(7):1019-1022. PMID: 31054164
  8. Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Mitochondrially derived peptides as novel regulators of metabolism. Free Radic Biol Med. 2016;100:182-193. PMID: 27216708
  9. Ming W, Lu G, Xin S, et al. Mitochondria related peptide MOTS-c suppresses ovarian cancer progression by attenuating USP7-mediated LARS1 deubiquitination. Adv Sci (Weinh). 2024;11(43):e2405620. PMID: 39428972
  10. Lu H, Wei M, Zhai Y, et al. MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Int J Mol Sci. 2022;23(19):11991. PMID: 36233287